| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8820315 | Respiratory Medicine Case Reports | 2018 | 5 Pages |
Abstract
Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX)Â +Â carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTXÂ +Â CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTXÂ +Â CBDCA for treating carcinosarcoma with ILD.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Hideyuki Niwa, Sakiko Otani, Norihiro Nakada, Jiichiro Sasaki, Hideo Saka, Noriyuki Masuda,